These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17272966)

  • 1. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.
    Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA
    Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
    Stocchi F; Zappia M; Dall'Armi V; Kulisevsky J; Lamberti P; Obeso JA;
    Mov Disord; 2010 Sep; 25(12):1881-7. PubMed ID: 20669296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study.
    Zangaglia R; Stocchi F; Sciarretta M; Antonini A; Mancini F; Guidi M; Martignoni E; Pacchetti C
    Clin Neuropharmacol; 2010; 33(2):61-6. PubMed ID: 19935405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
    Blindauer K; Shoulson I; Oakes D; Kieburtz K; Schwid S; Fahn S; Stern M; Goetz C; Nutt J; Goren S; Sayag N; Scolnik M; Levy R; Eyal E; Salzman P; Pagano M;
    Arch Neurol; 2006 Feb; 63(2):210-6. PubMed ID: 16476809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
    Hutton JT; Morris JL
    Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease.
    Stocchi F; Vacca L
    Minerva Med; 2019 Dec; 110(6):575-585. PubMed ID: 31965781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
    Diamond SG; Markham CH; Treciokas LJ
    Ann Neurol; 1978 Mar; 3(3):267-72. PubMed ID: 352236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo.
    Stocchi F; Barbato L; Bramante L; Bonamartini A; Ruggieri S
    Funct Neurol; 1994; 9(5):259-64. PubMed ID: 7750809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.